Intravenous Immunoglobulin Market Trends, Demands and Business Outlook 2022-2030

The global IVIG market is driven by factors such as high prevalence of diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP) and hypogammaglobulinemia coupled with surge in geriatric population and rise in the number of hemophilic patients. In addition, increase in production of immunoglobulin with better plasma quality using advanced purification techniques is expected to supplement the market growth. On the other hand, technological advancements in IVIG products are anticipated to provide lucrative opportunities in the market in near future. However, stringent government regulations towards IVIG products and side effects associated with the use of IVIG impede the growth of the market.

The global intravenous immunoglobulin market was valued at $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.

Request Sample Report at: 

https://www.alliedmarketresearch.com/request-sample/325

North America to continue its dominance throughout 2022 

North America occupied nearly half of the global market revenue in 2017 and is expected to retain its dominance from 2018 to 2025, owing to the high adoption rate of IVIG treatments across countries in the region supplemented with the presence of high-profile plasma production facilities. Meanwhile, LAMEA is expected to grow at the highest CAGR of 10% during the forecast period, as the region has witnessed a significant increase in the incidence of immunological & neurological diseases. The other regions analyzed in the report include Europe and Asia-Pacific.

Rise in prevalence of autoimmune disorders across the globe and surge in demand for intravenous immunoglobulin for treating neurological disorders supplement the growth of the intravenous immunoglobulin (IVIG) market. 

Key Findings of the Intravenous Immunoglobulin (IVIG) Market:

  • Myasthenia gravis segment is projected to grow at the highest rate during the forecast period.
  • Hypogammaglobulinemia was the largest revenue contributor in 2017 and is expected to continue its dominance throughout the forecast period.
  • North America dominated the global intravenous immunoglobulin market in 2017.
  • LAMEA is estimated to grow at the highest CAGR of 10.3% from 2018-2025.

In 2017, North America accounted for the largest share in the global market, followed by Asia-Pacific. The major factors responsible for the growth of the intravenous market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. coupled with the presence of large plasma production facilities.

Key market players 

The key players analyzed in the report include Baxter International Inc., CSL Ltd., Grifols, S.A., Octapharma AG, Kedrion Biopharma Inc., LFB Group, Biotest AG, China Biologics Products, Inc., Shire (Baxalta), and Bayer AG. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.

Leave a comment

Your email address will not be published.